Casdin Capital as of March 31, 2016
Portfolio Holdings for Casdin Capital
Casdin Capital holds 26 positions in its portfolio as reported in the March 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Loxo Oncology | 7.8 | $6.8M | 250k | 27.34 | |
| Epizyme | 7.6 | $6.6M | 545k | 12.12 | |
| Foundation Medicine | 7.0 | $6.1M | 335k | 18.18 | |
| Sage Therapeutics (SAGE) | 7.0 | $6.1M | 189k | 32.06 | |
| Agios Pharmaceuticals (AGIO) | 6.9 | $6.0M | 148k | 40.60 | |
| Blueprint Medicines (BPMC) | 6.7 | $5.8M | 321k | 18.05 | |
| Alnylam Pharmaceuticals (ALNY) | 6.5 | $5.6M | 90k | 62.77 | |
| Bluebird Bio | 5.8 | $5.1M | 120k | 42.50 | |
| Myokardia | 5.8 | $5.1M | 475k | 10.71 | |
| Spark Therapeutics | 5.8 | $5.0M | 170k | 29.51 | |
| Cytomx Therapeutics (CTMX) | 4.8 | $4.1M | 321k | 12.90 | |
| Kite Pharma | 4.0 | $3.4M | 75k | 45.91 | |
| Voyager Therapeutics (VYGR) | 3.4 | $3.0M | 339k | 8.73 | |
| Editas Medicine (EDIT) | 3.4 | $3.0M | 86k | 34.54 | |
| Dex (DXCM) | 3.1 | $2.7M | 40k | 67.90 | |
| SPDR S&P Biotech (XBI) | 3.0 | $2.6M | 50k | 51.66 | |
| Avexis | 2.0 | $1.7M | 63k | 27.24 | |
| Global Blood Therapeutics In | 1.9 | $1.7M | 105k | 15.86 | |
| Genomic Health | 1.6 | $1.4M | 55k | 24.76 | |
| Bristol Myers Squibb (BMY) | 1.5 | $1.3M | 21k | 63.86 | |
| Biogen Idec (BIIB) | 1.5 | $1.3M | 5.0k | 260.40 | |
| Beigene (ONC) | 1.1 | $953k | 33k | 29.32 | |
| Ignyta | 0.8 | $745k | 110k | 6.77 | |
| EXACT Sciences Corporation (EXAS) | 0.5 | $404k | 60k | 6.73 | |
| Medidata Solutions | 0.4 | $387k | 10k | 38.70 | |
| Oxford Immunotec Global | 0.2 | $198k | 20k | 9.90 |
